338 related articles for article (PubMed ID: 15359574)
1. Transport characteristics of fexofenadine in the Caco-2 cell model.
Petri N; Tannergren C; Rungstad D; Lennernäs H
Pharm Res; 2004 Aug; 21(8):1398-404. PubMed ID: 15359574
[TBL] [Abstract][Full Text] [Related]
2. Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters.
Ming X; Knight BM; Thakker DR
Mol Pharm; 2011 Oct; 8(5):1677-86. PubMed ID: 21780830
[TBL] [Abstract][Full Text] [Related]
3. Transport characteristics of tryptanthrin and its inhibitory effect on P-gp and MRP2 in Caco-2 cells.
Zhu X; Zhang X; Ma G; Yan J; Wang H; Yang Q
J Pharm Pharm Sci; 2011; 14(3):325-35. PubMed ID: 21824448
[TBL] [Abstract][Full Text] [Related]
4. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
Dahan A; Sabit H; Amidon GL
AAPS J; 2009 Jun; 11(2):205-13. PubMed ID: 19319690
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Wu X; Whitfield LR; Stewart BH
Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037
[TBL] [Abstract][Full Text] [Related]
6. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir.
Perloff MD; von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 2002 Nov; 42(11):1269-74. PubMed ID: 12412827
[TBL] [Abstract][Full Text] [Related]
7. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
8. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.
Dresser GK; Bailey DG; Leake BF; Schwarz UI; Dawson PA; Freeman DJ; Kim RB
Clin Pharmacol Ther; 2002 Jan; 71(1):11-20. PubMed ID: 11823753
[TBL] [Abstract][Full Text] [Related]
9. Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: Involvement of P-glycoprotein inhibition.
Bedada SK; Yellu NR; Neerati P
Pharmacol Rep; 2016 Apr; 68(2):338-43. PubMed ID: 26922536
[TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter.
Horie K; Tang F; Borchardt RT
Pharm Res; 2003 Feb; 20(2):161-8. PubMed ID: 12636153
[TBL] [Abstract][Full Text] [Related]
11. Transporter-mediated intestinal absorption of fexofenadine in rats.
Kikuchi A; Nozawa T; Wakasawa T; Maeda T; Tamai I
Drug Metab Pharmacokinet; 2006 Aug; 21(4):308-14. PubMed ID: 16946558
[TBL] [Abstract][Full Text] [Related]
12. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Cvetkovic M; Leake B; Fromm MF; Wilkinson GR; Kim RB
Drug Metab Dispos; 1999 Aug; 27(8):866-71. PubMed ID: 10421612
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers.
Liang E; Proudfoot J; Yazdanian M
Pharm Res; 2000 Oct; 17(10):1168-74. PubMed ID: 11145220
[TBL] [Abstract][Full Text] [Related]
14. Enantioselective uptake of fexofenadine by Caco-2 cells as model intestinal epithelial cells.
Togami K; Tosaki Y; Chono S; Morimoto K; Hayasaka M; Tada H
J Pharm Pharmacol; 2013 Jan; 65(1):22-9. PubMed ID: 23215684
[TBL] [Abstract][Full Text] [Related]
15. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine.
Tannergren C; Petri N; Knutson L; Hedeland M; Bondesson U; Lennernäs H
Clin Pharmacol Ther; 2003 Nov; 74(5):423-36. PubMed ID: 14586383
[TBL] [Abstract][Full Text] [Related]
16. Characterization of efflux transporters involved in distribution and disposition of apixaban.
Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
[TBL] [Abstract][Full Text] [Related]
17. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein.
Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
J Pharm Sci; 1999 Oct; 88(10):1067-72. PubMed ID: 10514357
[TBL] [Abstract][Full Text] [Related]
18. The impact of P-glycoprotein mediated efflux on absorption of 11 sedating and less-sedating antihistamines using Caco-2 monolayers.
Crowe A; Wright C
Xenobiotica; 2012 Jun; 42(6):538-49. PubMed ID: 22188412
[TBL] [Abstract][Full Text] [Related]
19. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
[TBL] [Abstract][Full Text] [Related]
20. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells.
Su Y; Zhang X; Sinko PJ
Mol Pharm; 2004 Jan; 1(1):49-56. PubMed ID: 15832500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]